EUVIMEDEUVIMED entdecken
CrossrefInfokarte

The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer

Masashi Kasajima, Satoshi Igawa, Hiroya Manaka, Kaori Yamada, Yuki Akazawa, Hideaki Manabe, Yuri Yagami, Hiroki Yamamoto, Hiroki Ito, Nobuki Kaizuka, Yoshiro Nakahara, Takashi Sato, Hisashi Mitshufuji, Masanori Yokoba, Masaru Kubota, Jiichiro Sasaki, Katsuhiko Naoki

Oncology · 2023 · 101 (1) · 69-76

DOI: 10.1159/000526964 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Predictors of the effectiveness of immune checkpoint inhibitor (ICI) monotherapy in previously treated patients with non-small cell lung cancer (NSCLC) remain ill-defined. We investigated whether the Glasgow prognostic score (GPS) could serve as such predictors. Methods: Eighty patients treated with pembrolizumab or atezolizumab monotherapy as second- or subsequent-line therapy for NSCLC were retrospectively reviewed, and the associations between GPS, body mass index (BMI), and each of progression-free survival (PFS) and overall survival (OS) were assessed. Results: The median follow-up period was 11.1 months. Patients with a BMI ≥20.4 kg/m2 had significantly longer PFS and OS (3.7 and 22.2 month, respectively) than did those with a BMI

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →